Metformin synergizes with rapamycin to inhibit the growth of pancreatic cancer in vitro and in vivo

Oncology Letters

Volumn 15, Issue 2, 2018, Pages 1811-1816

  Zhang, Jia Wei ^a   Zhao, Fan ^a   Sun, Qing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Metformin; Pancreatic cancer; Rapamycin

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MTT ASSAY; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; TUMOR VOLUME; WESTERN BLOTTING;

EID: 85038441964     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2017.7444     Document Type: Article

References (36)

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin 66: 7-30, 2016.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin 66: 115-132, 2016.
3. Ding B, Wahid MA, Wang Z, Xie C, Thakkar A, Prabhu S and Wang J: Triptolide and celastrol loaded silk fibroin nanoparticles show synergistic effect against human pancreatic cancer cells. Nanoscale 9: 11739-11753, 2017.
4. Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A, La Vecchia C, Mancia G and Corrao G: Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: A meta-analysis. Oncologist 17: 813-822, 2012.
5. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M and Li D: Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 18: 2905-2912, 2012.
6. Bodmer M, Becker C, Meier C, Jick SS and Meier CR: Use of antidiabetic agents and the risk of pancreatic cancer: A case-control analysis. Am J Gastroenterol 107: 620-626, 2012.
7. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH and Huang YC: Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: A representative population prospective cohort study of 800,000 individuals. BMC Cancer 11: 20, 2011.
8. Mohammed A, Janakiram NB, Brewer M, Ritchie RL, Marya A, Lightfoot S, Steele VE and Rao CV: Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling. Transl Oncol 6: 649-659, 2013.
9. Karnevi E, Said K, Andersso R and Rosendahl AH: Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer 13: 235, 2013.
10. Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J and Rozengurt E: Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS One 8: e57289, 2013.
11. Vallianou NG, Evangelopoulos A and Kazazis C3: Metformin and cancer. Rev Diabet Stud 10: 228-235, 2013.
12. Cifarelli V, Lashinger LM, Devlin KL, Dunlap SM, Huang J, Kaaks R, Pollak MN and Hursting SD: Metformin and rapamycin reduce pancreatic cancer growth in obese prediabetic mice by distinct microRNA-regulated mechanisms. Diabetes 64: 1632-1642, 2015.
13. National Research Council: Guide for the Care and Use of Laboratory Animals. 8th edition. National Acadamies Press. Washington, DC, 2011.
14. Simon R, Mirlacher M and Sauter G: Immunohistochemical analysis of tissue microarrays. Methods Mol Biol 664: 113-126, 2010.
15. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
16. Chou TC and Martin N: CompuSyn for drug combinations and for general dose-effect analysis. Combosyn, Inc., Paramus, NJ, 2005.
17. Guertin DA and Sabatini DM: An expanding role for mTOR in cancer. Trends Mol Med 11: 353-361, 2005.
18. Rice S, Pellat L, Ahmetaga A, Bano G, Mason HD and Whitehead SA: Dual effect of metformin on growth inhibition and oestradiol productionin breast cancer cells. Int J Mol Med 35: 1088-1094, 2015.
19. Zakikhani M, Blouin MJ, Piura E and Pollak MN: Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 123: 271-279, 2010.
20. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
21. Saha A, Blando J, Tremmel L and DiGiovanni J: Effect of metformin, rapamycin, and their combination on growth and progression of prostate tumors in HiMyc mice. Cancer Prev Res (Phila) 8: 597-606, 2015.
22. Wang Y, Wei J, Li L, Fan C and Sun Y: Combined use of metformin and everolimus is synergistic in the treatment of breast cancer cells. Oncol Res 22: 193-201, 2014.
23. Zi FM, He JS, Li Y, Wu C, Yang L, Yang Y, Wang LJ, He DH, Zhao Y, Wu WJ, et al: Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models. Cancer Lett 356: 443-453, 2015.
24. Hanly EK, Bednarczyk RB, Tuli NY, Moscatello AL, Halicka HD, Li J, Geliebter J, Darzynkiewicz Z and Tiwari RK: mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib. Oncotarget 6: 39702-39713, 2015.
25. O'Brien AJ, Villani LA, Broadfield LA, Houde VP, Galic S, Blandino G, Kemp BE, Tsakiridis T, Muti P and Steinberg GR: Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis. Biochem J 469: 177-187, 2015.
26. Yue W, Zheng X, Lin Y, Yang CS, Xu Q, Carpizo D, Huang H, DiPaola RS and Tan XL: Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2. Oncotarget 6: 21208-21224, 2015.
27. Ling S, Feng T, Ke Q, Fan N, Li L, Li Z, Dong C, Wang C, Xu F, Li Y and Wang L: Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines. Oncol Rep 31: 2611-2618, 2014.
28. Ling S, Tian Y, Zhang H, Jia K, Feng T, Sun D, Gao Z, Xu F, Hou Z, Li Y and Wang L: Metformin reverses multidrug resis-tance in human hepatocellular carcinoma Bel-7402/5-fluorouracil cells. Mol Med Rep 10: 2891-2897, 2014.
29. Zhu M, Zhang Q, Wang X, Kang L, Yang Y, Liu Y, Yang L, Li J, Yang L, Liu J, et al: Metformin potentiates anti-tumor effect of resveratrol on pancreatic cancer by down-regulation of VEGF-B signaling pathway. Oncotarget 7: 84190-84200, 2016.
30. Driscoll DR, Karim SA, Sano M, Gay DM, Jacob W, Yu J, Mizukami Y, Gopinathan A, Jodrell DI, Evans TR, et al: mTORC2 Signaling drives the development and progression of pancreatic cancer. Cancer Res 76: 6911-6923, 2016.
31. Lipner MB, Marayati R, Deng Y, Wang X, Raftery L, O'Neil BH and Yeh JJ: Metformin treatment does not inhibit growth of pancreatic cancer patient-derived Xenografts. PLoS One 11: e0147113, 2016.
32. Wei F, Zhang Y, Geng L, Zhang P, Wang G and Liu Y: mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer. Int J Mol Sci 16: 3267-3282, 2015.
33. Zagouri F, Sergentanis TN, Chrysikos D, Zografos CG, Papadimitriou CA, Dimopoulos MA, Filipits M and Bartsch R: Molecularly targeted therapies in metastatic pancreatic cancer: A systematic review. Pancreas 42: 760-773, 2013.
34. Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Villaroel MC, Zhao M, Rajeshkumar NV, Jimeno A, Donehower R, et al: Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer 103: 649-655, 2010.
35. Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, Davis D, Zhang Y, Wolff RA and Abbruzzese JL: Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: Results of two phase II studies. BMC Cancer 10: 368, 2010.
36. Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP and Fuchs CS: Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 27: 193-198, 2009.